SecBot SecBot
6-K ·Filed Sep 1, 2026

AZN

ASTRAZENECA PLC
NEUTRAL
Impact 3/10
Horizonimmediate Processed2mo ago SEC0001654954-26-007992
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine debt issuance with no material read-through for AZN common equity. Monitor upcoming quarterly results for any change in leverage or interest coverage ratios, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$162.47
T+0 close · Sep 1, 2026 · via day close
Latest settled
+0.47%
T+20 · $163.23 · next T+60 in 8d
Vs SPY
−0.71%
α at T+20
Latest observation
+14.90%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $162.47entry
  2. T+1 · 3mo ago −0.52%α −0.96% · $161.63
  3. T+5 · 2mo ago −3.40%α −3.49% · $156.94
  4. T+20 · 7w ago +0.47%α −0.71% · $163.23
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca's wholly owned subsidiary, AstraZeneca Finance LLC, has admitted EUR 2.55 billion in four tranches of fixed-rate notes to trading on the London Stock Exchange. This is a routine debt capital markets transaction to refinance or fund general corporate purposes, with no new material operational or financial information disclosed for the common equity. The offering is credit-neutral for the common stock, as it adds leverage but at moderate fixed rates and extends the maturity profile.

Key Facts

  • AstraZeneca Finance LLC issued EUR 2.55 billion aggregate nominal amount of notes across four tranches.
  • Tranches: EUR 700M 3.402% notes due 2030, EUR 600M 3.652% notes due 2032, EUR 500M 3.923% notes due 2035, EUR 750M 4.169% notes due 2038.
  • All notes admitted to trading on the London Stock Exchange's Main Market on 1 September 2026.
  • Issuance is under a base prospectus dated 9 June 2026.
  • The offering is a routine debt capital management transaction, not an equity event, and does not dilute common shareholders.

Financial Impact

EUR 2.55 billion in new debt issued at fixed rates between 3.402% and 4.169%, extending maturities to 2030-2038. No impact on common equity or earnings per share.

debtinterest expense

Risk Factors

  • Increased leverage and interest expense from EUR 2.55B in new debt.
  • Potential credit rating impact if debt-to-EBITDA rises materially, though current investment-grade profile likely absorbs this issuance.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007992
Document: 0001654954-26-007992-index-headers.html0001654954-26-007992
Document: 0001654954-26-007992-index.html0001654954-26-007992
Document: 0001654954-26-007992.txt0001654954-26-007992

Track record

77 reports on AZN

Performance horizon

19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026